Medical Equipment

Rising Breast Cancer Incidence Is Driving Growth In The Breast Cancer Screening Test Market

April 10, 2026April 10, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Estimated Market Size Of The Breast Cancer Screening Test Market In 2026, And How Will Its Value Evolve By 2030?

The breast cancer screening test market has demonstrated robust growth over recent years. Projections indicate its expansion from $2.49 billion in 2025 to $2.69 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.3%. Historically, this growth has been driven by factors such as enhanced awareness of breast cancer incidence, the broad implementation of mammography screening initiatives, the enlargement of diagnostic laboratory facilities, the provision of uniform screening protocols, and escalating public health screening campaigns.

The breast cancer screening test market is projected to experience substantial expansion in the coming years. This market is anticipated to reach $3.68 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.1%. The anticipated growth throughout this forecast period stems from several factors, including the increasing integration of personalized cancer screening protocols, the wider utilization of AI-powered diagnostic tools, the broadening adoption of genetic testing, a heightened emphasis on detecting cancer in its early stages, and greater investments in preventive oncology services. Key trends identified for the forecast timeframe encompass the rising uptake of advanced imaging-based screening tests, the expanding application of genetic and molecular diagnostics, the increasing incorporation of AI in image interpretation, the development of multi-modal screening methodologies, and a stronger focus on diagnostics that are both early and preventive.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24180&type=smp

What Key Factors Are Affecting The Breast Cancer Screening Test Market Demand?

An anticipated increase in breast cancer cases is projected to stimulate expansion within the breast cancer screening test market moving ahead. Breast cancer is defined by the uncontrolled proliferation of abnormal cells within breast tissue, potentially forming tumors and metastasizing elsewhere in the body. This uptick in breast cancer cases stems from the world’s aging populace, given that increasing age is a primary risk factor for the condition, and extended life expectancies contribute to a larger pool of individuals susceptible to it. Early detection of the disease through breast cancer screening tests improves prospects for successful treatment and lowers mortality associated with breast cancer. As an illustration, in March 2025, Breastcancer.org, a US nonprofit, anticipates approximately 316,950 women will be diagnosed with invasive breast cancer in 2025, alongside 59,080 new instances of non-invasive ductal carcinoma in situ (DCIS). Consequently, the escalating incidence of breast cancer is a key factor propelling the expansion of the breast cancer screening test market.

What Segment Categories Shape The Breast Cancer Screening Test Market Segment Landscape?

The breast cancer screening test market covered in this report is segmented –

1) By Diagnostic Test Type: Blood Marker Test, Imaging Test, Genetic Test, Immunohistochemistry Test

2) By Risk Level: High-risk Population, Moderate-risk Population, Average-risk Population

3) By End User: Hospitals, Diagnostic Centres, Cancer Institutes, Research Laboratories

Subsegments:

1) By Blood Marker Test: Circulating Tumor Cells (Ctcs) Test, Gene Expression Profiling Test, Circulating Tumor Dna (Ctdna) Test, Proteomic Biomarker Test

2) By Imaging Test: Mammography, Magnetic Resonance Imaging Screening Test, Molecular Breast Imaging Test, Positron Emission Mammography, Ultrasound

3) By Genetic Test: Fluorescence In Situ Hybridization, Her Gene Test

4) By Immunohistochemistry (Ihc) Test: Estrogen Receptor (Er) Test, Ki-67 Proliferation Marker Test, Progesterone Receptor (Pr) Test, Her2 Or Neu Test

What Trends Are Influencing Changes In The Breast Cancer Screening Test Market?

Major companies in the breast cancer screening test market are concentrating on developing innovative products, such as mobile cancer screening units. This strategy aims to enhance accessibility, improve early detection rates, and expand screening coverage in underserved and remote areas. A mobile cancer screening unit functions as a transportable facility equipped with diagnostic imaging technologies like mammography, designed to deliver on-site breast cancer screening services in remote or underserved locations. For instance, in September 2024, Granules India Ltd., an India-based pharmaceutical company, launched a Breast Health Express to boost breast cancer screening in underprivileged communities. This unit is fitted with state-of-the-art mammography and ultrasound technology, enabling high-quality screenings to be performed on the go. The initiative focuses on reaching underserved and rural communities where access to healthcare facilities may be limited, thereby ensuring women in remote areas can access crucial early detection services.

Who Are The Companies Operating Across The Breast Cancer Screening Test Market Value Chain?

Major companies operating in the breast cancer screening test market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthcare GmbH, Fujifilm Corporation, Koninklijke Philips NV, GE HealthCare Technologies Inc., Quest Diagnostics Incorporated, Hologic Inc., Hitachi High-Tech Corporation, Exact Sciences Corporation, Natera Inc., Myriad Genetics Inc., Canon Medical Systems Corporation, Provista Diagnostics Inc., Niramai Health Analytix Pvt. Ltd., Kheiron Medical Technologies Limited, UE LifeSciences Inc., BD (Becton Dickinson and Company), Agilent Technologies Inc.

Get The Full Breast Cancer Screening Test Market Report:

https://www.thebusinessresearchcompany.com/report/breast-cancer-screening-test-global-market-report

Which Region Holds The Highest Market Share In The Breast Cancer Screening Test Market?

North America was the largest region in the breast cancer screening test market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast cancer screening test market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Breast Cancer Screening Test Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/customise?id=24180&type=smp

Browse Through More Reports Similar to the Global Breast Cancer Screening Test Market 2026, By The Business Research Company

Cellular Health Screening Market Report 2026

https://www.thebusinessresearchcompany.com/report/cellular-health-screening-global-market-report

Next Generation Gynecological Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/next-generation-gynecological-cancer-diagnostics-global-market-report

Breast Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795